Immuno-oncology company Imugene Limited (ASX:IMU) is heading to market with a capital raising.
The ASX has granted the company a trading halt, with its shares placed in pre-open.
Imugene is developing B-cell based immunotherapies, known as HER-Vaxx, for HER-2 positive gastric and breast cancer.
The halt will remain in place until the opening of trade on Wednesday 5th November 2014, or earlier if an announcement is made to the market.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.